Curtis Lachowiez is an Oncology physician affiliated with Oregon Health & Science University. OpenAlex indexes 196 publications with 1,563 citations (h-index 19); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3181 SW Sam Jackson Park Rd
Portland, OR 972393011
Telephone
503-494-5058Provider last certified this registry record 26 May 2022.
Clinical trials
- Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia
Sponsor: OHSU Knight Cancer Institute
- Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia
Sponsor: OHSU Knight Cancer Institute
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Astellas Pharma US IncProgram year20251 payment
- SERVIER PHARMACEUTICALS LLCProgram year20251 payment
- Genentech USA, Inc.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
27.8%Azole Antifungal11.9%Posaconazole66%Voriconazole34%Part D<11 patientsFluoroquinolone Antibacterial10.7%Levofloxacin100%Part D≥21 patients+ 2 more classes in this area
Cancer & immunology
20.9%BCL-2 Inhibitor12.6%Venclexta100%Part D≥21 patientsIsocitrate Dehydrogenase 1 Inhibitor5.9%Tibsovo100%Part D<11 patients+ 1 more class in this area
Dermatology
20.5%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor20.5%Acyclovir100%Part D≥24 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed <i>NPM1</i> -Mutated or <i>KMT2A</i> -Rearranged AML
Journal of Clinical Oncology
2025 - Multimodal and Data-Driven Assessment of Myeloid Neoplasms Refines Classification across Disease States
Blood Cancer Discovery
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Eric Orwoll, MD
Oregon Health & Science University
Aaron Caughey, MD
Oregon Health & Science University
Tomasz Beer, MD
Oregon Health & Science University
John Nutt, MD
Oregon Health & Science University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”